4th Quarter - Report

KOUNTOUPES DENHAM CARR & REID, LLC for GLENMARK PHARMACEUTICALS, INC., USA

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues related to affordability, essential medicine manufacturing and pharmaceuticals. General issues related to the generic drug industry. Issues related to H.R. 2853, the BLOCKING Act of 2021. Issues related to pharmaceutical provisions in H.R. 5376, the Build Back Better Act.

Foreign entity interest: Glenmark Pharmaceuticals Inc. USA (GPI) is the North American division of Glenmark Pharmaceuticals, Ltd. (GPL), a corporation formed under the laws of India. GPL, as GPIs upstream foreign parent, has an interest in the listed issues.

LobbyistCovered position, as disclosed
ADAM HECHAVARRIA —
LISA KOUNTOUPES —

Contacted: SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Bills named: H.R. 5376 (117th), H.R. 2853 (117th)

Health Issues HCR

General education about the generic pharmaceuticval industry.

Foreign entity interest: Glenmark Pharmaceuticals Inc. USA (GPI) is the North American division of Glenmark Pharmaceuticals, Ltd. (GPL), a corporation formed under the laws of India. GPL, as GPIs upstream foreign parent, has an interest in the listed issues.

LobbyistCovered position, as disclosed
ADAM HECHAVARRIA —
LISA KOUNTOUPES —

Contacted: Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.